Innovative Chinese Immunotherapy, Sintilimab Sets New Survival Records for Upper Gastrointestinal Cancers
At the 2023 American Association for Cancer Research (AACR) annual meeting held on April 17, groundbreaking long-term follow-up data from studies on the Chinese innovative PD-1 inhibitor, Sintilimab, was unveiled. The findings span from phase III clinical trials for esophageal cancer (ORIENT-15) and gastric cancer (ORIENT-16). The results from these trials have set new longevity records for first-line treatments of these cancers in China.